What's on this Page
What is Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine DTaP Haemophilus influenzae type b Conjugate Vaccine Hepatitis B Vaccine Recombinant Inactivated Poliovirus Vaccine IPV
Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine DTaP Haemophilus influenzae type b Conjugate Vaccine Hepatitis B Vaccine Recombinant Inactivated Poliovirus Vaccine IPV (Vaxelis) is a combination vaccine used for immunization against diphtheria, tetanus, pertussis, Haemophilus influenzae type b, hepatitis B, and polio.
It is indicated as a 3-dose series for infants and children 6 weeks through 4 years of age.
The administration of combination vaccines such as Vaxelis is believed to reduce cost and improve compliance with the recommended vaccination schedule by reducing the number of injections received per physician visit.
The pertussis antigens in Vaxelis are the same as those found in Pentacel, Quadracel, and Daptacel; therefore, these products are recommended to complete the primary and pertussis vaccination series in patients who receive the 3-dose series with Vaxelis.
In 1997, adverse reactions associated with the use of whole-cell pertussis vaccines (DTP) led to recommendations by the Advisory Committee on Immunization Practices (ACIP) that acellular pertussis vaccines (DTaP) be used for routine childhood vaccination in the United States.
In 2000, the ACIP recommended that IPV be used for routine childhood polio vaccination in the United States instead of oral poliovirus vaccine (OPV), prompted in part by the rare but serious side-effect of OPV-associated paralytic poliomyelitis.
Vaxelis is FDA-approved for use in infants as young as 6 weeks; ideally, administration should occur at 2, 4, and 6 months of age.
Indications
- diphtheria prophylaxis
- Haemophilus influenzae type b prophylaxis
- hepatitis B prophylaxis
- pertussis prophylaxis
- poliovirus prophylaxis
- tetanus prophylaxis
Contraindications
- agammaglobulinemia
- albumin hypersensitivity
- anticoagulant therapy
- bleeding
- breast-feeding
- chemotherapy
- coagulopathy
- coma
- encephalopathy
- fever
- Guillain-Barre syndrome
- hemophilia
- human immunodeficiency virus (HIV) infection
- hypogammaglobulinemia
- immunosuppression
- infection
- intravenous administration
- laboratory test interference
- neomycin hypersensitivity
- neoplastic disease
- neurological disease
- polymyxin hypersensitivity
- polysorbate 80 hypersensitivity
- pregnancy
- premature neonates
- radiation therapy
- seizure disorder
- seizures
- severe combined immunodeficiency (SCID)
- shock
- subcutaneous administration
- thrombocytopenia
- vitamin K deficiency
- yeast hypersensitivity
Interactions
No information is available regarding drug interactions
